Russian Heart Failure Journal 2010year Efficacy of trimetazidine MB in composite treatment of moderate heart failure and asymptomatic left ventricle dysfunction in patients with acute myocardial infarction


To access this material please log in or register

Register Authorize
2010/

Efficacy of trimetazidine MB in composite treatment of moderate heart failure and asymptomatic left ventricle dysfunction in patients with acute myocardial infarction

Matyushin G. V., Veselkova N. S., Kuskaev A. P., Sergeeva A. S.

Keywords: asymptomatic dysfunction, myocardial infarction, left ventricle, Preductal, heart failure, efficacy

DOI: 10.18087/rhfj.2010.5.1396

Background. Positive effect of trimetazidine in patients with symptomatic CHF or asymptomatic LV dysfunction on standard therapy was previously demonstrated. However, there is no data on efficacy of trimetazidine MB in patients with MI and symptomatic CHF or asymptomatic LV dysfunction. Objective. To investigate and substantiate the possibility of Trimetazidine MR usage in the treatment of moderate HF and asymptomatic left ventricular dysfunction in patients with MI. Materials and methods. In this open randomized study 120 patients with MI and moderate CH (I–II FC) or asymptomatic LV dysfunction took part. Efficacy of standard therapy and its combination with trimetazidine MB (preductal MB) was evaluated. During 6-months follow-up dynamics of clinical condition and indicators of left ventricular ejection fraction were analysed. Results. In patients treated with trimetazidine MB less relapses or recurrent MI occurred as well as recurrent hospitalizations (including decompensated CHF). Significant positive dynamics of clinical condition, LVEF, significant decrease of CHF FC were observed. Thus, trimetazidine MB can be recommended as a part of complex therapy of patients with MI and moderate chronic heart failure or asymptomatic LV dysfunction.
  1. World Health Organization. The World Health Report 2003: Shaping the future 2003. Available at: http://www.who.int / whr / 2003 / en / overview_en. pdf
  2. Медико-демографические показатели Российской Федерации – 2006 год. Статистические материалы. – Москва, 2007. – 188с.
  3. Оганов Р. Г., Мамедов М. Н. Национальные клинические рекомендации ВНОК. – М.: "Силицея-Полиграф", 2008. – 512с.
  4. Grynberg A. Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents. Curr Pharm Des. 2005;11 (4):489–509.
  5. Effect of 48‑h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project – Free Radicals. Eur Heart J. 2000;21 (18):1537–1546.
  6. Chazov EI, Lepakchin VK, Zharova EA et al. Trimetazidine in Angina Combination Therapy – the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12 (1):35–42.
  7. Коломеец Н. М., Бакшеев В. И., Зарубина Е. Г. и др. Метаболическая терапия триметазидином МВ у пациентов с кардиореспираторной патологией (результаты открытого проспективного исследования). Клиническая фармакология и терапия. 2009;18 (4):34–40.
  8. Шальнова С. А., Васюк Ю. А., Школьник Е. Л., Куликов К. Г. Ишеми­ческая болезнь сердца в условиях реальной клинической практики. Результаты эпидемиологического этапа исследования ПРИМА. Предуктал модифицированного высвобождения в лечении пациентов со стабильной стенокардией, перенесших инфаркт миокарда. Consilium Medicum. 2009;13 (5):122–126.
  9. Новицкая Э. Е., Барышникова Г. А. Эффективность триметазидина МВ у больных сахарным диабетом 2 типа, перенесших инфаркт миокарда. Сахарный диабет. 2009;2:58–61.
  10. Глезер Н. Г., Васильев С. В. Антиангинальная и противоишемическая эффективность Предуктала МВ у пациентов с нестабильной стенокардией. Кардиоваскулярная терапия и профилактика. 2009;8 (1):42–46.
  11. Елисеев О. М. Триметазидин (Предуктал). Новый подход в борьбе с ишемией миокарда. Тер. архив. 1996;68 (8):57–63.
  12. Лопатин Ю. М., Дронова Е. Н. Клинико-фармакоэкономические аспекты применения триметазидина модифицированного высвобождения у больных ИБС, подвергнутых коронарному шунтированию. Кардиология. 2009;49 (2):1–7.
  13. Kölbel F, Bada V. Trimetazidine in geriatric patients with stable angina pectoris: the tiger study. Int J Clin Pract. 2003;57 (10):867–870.
  14. Szwed H, Sadowski Z, Elikowski W et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22 (24):2267–2274.
  15. Васюк Ю. А., Школьник Е. Л. Возможности миокардиальных цитопротекторов в комплексном лечении больных ХСН ишемического генеза. Кардиология. 2006;46 (11):48–56.
  16. Di Napoli P, Di Giovanni P, Gaeta MA et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d’Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50 (5):585–589.
  17. El-Kady T, El-Sabban K, Gabaly M et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24‑month study. Am J Cardiovasc Drugs. 2005;5 (4):271–278.
  18. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J. 2007;28 (9):1102–1108.
  19. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3‑ketoacyl coenzyme A thiolase. Circ Res. 2000;86 (5):580–588.
  20. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol. 2003;17 (2):133–145.
  21. Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem. 1997;175 (1–2):153–162.
Matyushin G. V., Veselkova N. S., Kuskaev A. P. et al. Efficacy of trimetazidine MB in composite treatment of moderate heart failure and asymptomatic left ventricle dysfunction in patients with acute myocardial infarction. Russian Heart Failure Journal. 2010;11(5):276-280.

To access this material please log in or register

Register Authorize
Ru En